ConductScience.org, home
IL36R: interleukin 36 receptor
API referenceFor AI assistants

Gene · 8808

Papers947

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 947

Download this page as JSON
TitleJournalYearPMIDFound bySource
An Evolving Landscape in GPP Management: Recibokibart and the Prospect of Broader Access to IL-36 Receptor Blockade.Br J Dermatol202642710062PubTator, text miningPubMed
Japanese intractable and rare dermatologic diseases: From the official skin-centered nanbyo core to an illustrative mechanism-based framework.Intractable Rare Dis Res202642643679PubTator, text miningPubMed
Author Correction: IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation.Nat Immunol202642608477PubTator, text miningPubMed
Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.Pragmat Obs Res202642604245PubTator, text miningPubMed
INDIVIDUAL ARTICLE: Generalized Pustular Psoriasis: A Contemporary Review of Diagnosis, Pathophysiology, and IL-36 Pathway-Directed Management.J Drugs Dermatol202642555081PubTator, text miningPubMed
When Conventional Therapy Fails: Interleukin-36 Inhibition for Severe Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis in Systemic Lupus Erythematosus - A Case Report.Case Rep Dermatol202642524626PubTator, text miningPubMed
Mitochondrial and Epigenetic Drivers of Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease.Antioxidants (Basel)202642510568PubTator, text miningPubMed
A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.Am J Clin Exp Immunol202642487722PubTator, text miningPubMed
Management of Generalized Pustular Psoriasis Flare with Intravenous Spesolimab Followed by Long-Term Treatment with Subcutaneous Spesolimab: A Case Report.Case Rep Dermatol202642396388PubTator, text miningPubMed
IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.Int J Mol Sci202642196416PubTator, text miningPubMed
Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.NEJM Evid202642047557PubTator, text miningPubMed
IL-36 Receptor Antagonist Spesolimab for Generalized Pustular Psoriasis Combined with Palmoplantar Pustulosis: A Case Report.Clin Cosmet Investig Dermatol202642016539PubTator, text miningPubMed
Spesolimab for generalized pustular psoriasis: a prospective study with a 6-month follow-up.Clin Exp Dermatol202641999186PubTator, text miningPubMed
Unusual Presentation of Pustular Psoriasis on the Face: A Case Report.Cureus202641994815PubTator, text miningPubMed
The IL-36 Cytokine Rheostat: Hierarchical Regulation of Epithelial-Immune Crosstalk and Precision Therapy in Psoriatic and Related Dermatoses.Clin Cosmet Investig Dermatol202641924293PubTator, text miningPubMed
The multifaceted roles of interleukin-36 in liver diseases: from pathogenesis to therapeutic potential.Int Immunopharmacol202641880675PubTator, text miningPubMed
Genetic predisposition to coffee consumption and the association with the early risk of atherosclerosis.Sci Rep202641865070PubTator, text miningPubMed
Development of Pyoderma Gangrenosum in a Patient with Acquired Reactive Perforating Collagenosis.Case Rep Dermatol202641799558PubTator, text miningPubMed
Acute Generalized Exanthematous Pustulosis: An Integrated Study of 503 Cases with Emphasis on Drug Culprits, Clinical Features, Diagnosis and Treatment.J Inflamm Res202641783151PubTator, text miningPubMed
A case of delayed-onset postoperative pyoderma gangrenosum complicated with chronic myelomonocytic leukemia treated with systemic corticosteroids and spesolimab.JAAD Case Rep202641769072PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/8808/papers

API referenceFor AI assistants